Share Price, page-79

The update on Teva is the one I am waiting for - as marketing approval for this will not only generate a license fees, registration milestone payments and commercial milestone payments of up to US $1.7m.

Plus we need updates on progress all products as per announcement dated 21 June 2018 - one main  SUD - 005 as below

SUD-005 midazolam oral spray (epileptic seizures)Formulation work on SUD-005 is ongoing utilising SUDA’s permeation-enhancingtechnology to provide extended patent protection. The current formulation is flavouredstrawberry-mint to appeal to infants and as well as older children.There is strong interest in midazolam as a treatment for epileptic seizures within thepharmaceutical industry. In April 2018, UCB, a global pharmaceutical company, acquiredthe rights to Proximagen’s nasal spray of midazolam for US$150 million upfront andcontingent payments of up to US$220 million.SUDA has multiple partnering discussions ongoing regarding a global licence to SUD-005.